The Decoded Journal.
Regulatory, market-sequencing, and category notes from Decoded Longevity. Published when the work — not the calendar — is ready.
- Practitioner Tools
The OpenEvidence Alternative Stack for SEA/SA Practitioners
OpenEvidence remains gated behind a US National Provider Identifier check, locking out clinicians in Singapore, Johannesburg and everywhere between. The practical workaround is a three-tool stack — and it costs less than US$30 a month.
Published
2026-05-12
6 min
- Regulatory
Indonesia's October 2026 Halal Mandate — What Distributors Need to Know
BPJPH's 17 October 2026 deadline for cosmetics, supplements and chemical products is now five months away. Distributors without halal certification or registered SHLN by August 2026 should plan for delisting.
Published
2026-05-08
7 min
- Regulatory
ACD Singapore — The 39th and 40th Substance Class Changes
The ASEAN Cosmetic Committee's 2024-2025 meetings moved Acid Yellow 3 to Annex III with a 24-month grace ending 14 May 2026, restricted zinc pyrithione, and added phenacetin to the prohibited list. HSA's December 2025 annex update reflects all of it.
Published
2026-05-02
6 min
- Regulatory
GLP-1 Compounding in Sub-Saharan Africa — Regulatory Reality 2026
SAHPRA's March 2025 intention to declare compounded GLP-1s undesirable has not been finalised, and the trade continues. MCAZ Zimbabwe issued its first public Ozempic warning in June 2025. The compounding window is closing, unevenly.
Published
2026-04-28
7 min
- Practitioner Tools
The Practitioner Tool Stack — What 500+ SEA Clinics Actually Use
Pabau, Cliniko and Fresha dominate the practice-management layer; Heidi and Glass have become the de facto AI-scribe defaults. The premium versus mass-market split in Orchard Road versus Manila is wider than vendor websites suggest.
Published
2026-04-22
7 min
- practitioner-toolkit-intelligenceSG · MY · ID · TH · VN · PH
The seven AI and clinical-software tools every modern longevity-aesthetic practitioner should know.
From AI scribes to biomarker platforms, the seven-tool toolkit Decoded curated from forty-plus evaluated platforms. Regional viability verified for SEA and SA.
Last reviewed
2026-04-20
9 min
- clinical-equipment-intelligenceSG · MY · ID · TH · VN · PH
230V/50Hz, IEC 60335-2-53, and the SAHPRA Hazardous Substances Act — the equipment-import discipline practices skip and regret.
Voltage and frequency mismatch, refrigerant choice, and SAHPRA classification are the three places clinical equipment imports go wrong. A precise view on the discipline that prevents it.
Last reviewed
2026-04-20
8 min
- practice-intelligenceSG · MY · ID · TH · VN · PH
Running a company on an agent stack — what we have learned operating Decoded this way.
Decoded itself runs on an agent stack across content, partner intake, regulatory monitoring, and triage. A first-person view on what works, what fails, and what the practice version of this looks like.
Last reviewed
2026-04-20
9 min
- peptide-protocolsSG · MY · ID · TH · VN · PH
BPC-157 and the tissue-repair evidence base — what the clinical literature actually shows.
BPC-157 has built strong preclinical interest and a growing clinical literature. A precise view on what the evidence supports, where it is thin, and how practitioners are framing it inside their protocols.
Last reviewed
2026-04-18
8 min
- practice-intelligenceSG
Building a longevity practice in Singapore — regulatory, channel, and clinical considerations.
Singapore is the clearest setting in SEA to build a longevity practice and the most demanding on regulatory, premise, and claims discipline. A practical view of the build sequence in 2026.
Last reviewed
2026-04-18
9 min
- longevity-scienceSG · MY · ID · TH · VN · PH
GLP-1 adjacencies in longevity practice — what sits inside and outside the prescription line.
GLP-1 prescribing remains physician-led. The adjacencies — protocol design, body-composition tracking, nutritional support, and follow-on supplementation — sit inside practitioner scope. A view on where each line falls in 2026.
Last reviewed
2026-04-18
7 min
- ai-in-practiceSG · MY · ID · TH · VN · PH
How AI is reshaping the diagnostic workflow in aesthetic and functional medicine.
AI is changing intake, imaging analysis, and protocol design across aesthetic and functional practice. A view on where the assistance is real, where it overpromises, and what to evaluate before deployment.
Last reviewed
2026-04-18
8 min
- Regulatory
Thailand's FDA on Imported Aesthetic Devices — 2026 Updates
The Thai FDA's January 2026 Manufacturing License Announcement, effective May 2026, restructures how energy-based aesthetic devices are evaluated. HIFU and RF microneedling sit at Class 2-3 and now face activity-based facility scrutiny.
Published
2026-04-15
6 min
- Market sequencingID
Indonesia's premium skincare market — sequencing a 2026 launch around halal, BPOM, and channel rules.
Indonesia is the largest single skincare opportunity in ASEAN and the least forgiving on dossier and channel discipline. A sequencing view for a 2026 launch.
Last reviewed
2026-04-15
7 min
- CategorySG · MY · ID · TH · VN · PH
Aesthetic-device reimbursement and out-of-pocket dynamics across SEA — the picture for 2026.
Aesthetic-device economics across the six markets are largely out-of-pocket — but the variations matter, and the 2026 movement on a small set of indications is real.
Last reviewed
2026-04-15
6 min
- CategorySG · MY · ID · TH · VN · PH
GLP-1 adjacencies in the longevity line — what is in scope for distributors in Southeast Asia.
GLP-1 medications are out of scope for non-pharmaceutical distributors. The adjacencies — supplements, devices, and protocols — are not. A view on what is responsibly in scope and what is not.
Last reviewed
2026-04-15
6 min
- RegulatorySG
Singapore HSA — the 2026 therapeutic-products updates and where the supplement-to-therapeutic line moved.
HSA's 2026 therapeutic-products guidance refines the line between supplement and therapeutic product. A view on which SKU profiles cross the line and what reclassification means.
Last reviewed
2026-04-15
7 min
- Regulatory
Malaysia NPRA — Health Supplement vs. Pharmaceutical Classification
NPRA's Food-Drug Interphase framework is where most longevity supplements get caught. NMN, NR and similar bioactives sit closer to the drug boundary in Malaysia than in Singapore or Thailand.
Published
2026-04-08
6 min
- Regulatory
Philippines FDA — The CPR Process for Cosmetics & Health Supplements
The Philippine FDA's Certificate of Product Registration process is slower than its ASEAN neighbours but defines access to the BGC and Makati premium clinic concentration. Cosmetics run 15-30 working days under CPN; food supplements via CPR run 20-60.
Published
2026-04-01
6 min
- Regulatory
South Africa's SAHPRA — Complementary Medicines Reclassification 2026
SAHPRA's Category D complementary medicines framework is operational but unevenly enforced. The recent reclassification of paediatric zinc picolinate and selenium signals tighter scrutiny on what counts as a 'low risk' supplement.
Published
2026-03-25
6 min
- Market Intel
Vein & Veldt — The Vascular Health Category Nobody's Building
Cardiovascular disease drives 31% of global deaths, but the longevity industry over-indexes on metabolic and senolytic plays. Vascular tone, endothelial function and venous insufficiency are an underserved category — particularly in aging SEA and SSA urban professional segments.
Published
2026-03-18
7 min
- Regulatory
Vietnam's MOH — The Notification System for Wellness Products
Vietnam's Decree 46/2026 replaced the old self-declaration model with full pre-market registration for health supplements. The speed advantage versus neighbours has narrowed, but HCMC and Hanoi remain accessible if you respect the new dossier requirements.
Published
2026-03-11
6 min
- Distribution
Distribution Timeline — From Brand Inquiry to First Clinic Order
60-120 days from brand inquiry to first clinic order is the honest range for SEA/SSA distribution entry. The kill points are regulatory delays, payment terms misalignment, and COGS that doesn't survive 3-tier margin stacking.
Published
2026-03-04
6 min
- Practitioner Tools
AI Agents and Clinic Workflows — What's Real in 2026
AI scribes are the only clinic-AI category that has cleared the hype line by mid-2026. Heidi Health at US$150/month, supporting 2M+ weekly consults in 110 languages across 116 countries, is the only credible multilingual option for SEA. Marketing-AI and intake-AI remain mostly overpromised.
Published
2026-02-25
7 min
- Market Intel
The Botswana / Namibia Distribution Pattern — Underrated Markets
Botswana and Namibia are small populations with high per-capita income (Botswana US$7,696 nominal in 2024) and concentrated premium clinic networks in Gaborone and Windhoek. Regulatory paths are simpler than South Africa via ZAZIBONA priority routes — the markets reward operators who understand the scale.
Published
2026-02-18
7 min